https://www.selleckchem.com/pr....oducts/cetuximab.htm
To assess whether a model-based analysis increased statistical power over an analysis of final day volumes and provide insights into more efficient patient derived xenograft (PDX) study designs. Tumour xenograft time-series data was extracted from a public PDX drug treatment database. For all 2-arm studies the percent tumour growth inhibition (TGI) at day 14, 21 and 28 was calculated. Treatment effect was analysed using an un-paired, two-tailed -test (empirical) and a model-based analysis, likelihood ratio-test (LRT). In addition, a s
Like
Comment
Share
